| Citation |
Study type |
Case |
DC-vaccine treated |
Antigen source |
Culture of DC |
Dosage |
Immunological reaction |
Clinical response |
| [2] |
Case report |
1 |
R-GBM |
allogeneic MHC-I GBM peptides |
GM-CSF and IL-4; |
i.d. ½ wks (× 3) |
Increased TILs |
PD, OS:21m |
| [4] |
Phase I |
9 |
N-GBM(n=7), AA(n=2) |
autologous tumor specific, MHC-I |
GM-CSF and IL-4; |
s.c. ½ wks (× 3) |
SCR, TILs (CTL and Tm） |
Med OS; 455d |
| [3] |
Phase I |
8 |
GBM(n=5), AA(n=3) |
ATC |
GM-CSF, IL-4 and TNF-α |
i.d. 1/3 wks (× 9) |
Increased NK cells, IFN-γ |
PR(n=2); SD(n=4); PD(n=2); |
| [6] |
Phase I/II |
10 |
GBM(n=7), AA(n=3) |
ATL |
GM-CSF and IL-4 |
i.d. and/or i.t. (ommaya) 1/3 wks (× 10) |
Increased NK cells; DTH+; infiltration of T cells |
-- |
| [5] |
Phase I/II |
17 |
N-GBM, R-GBM |
ATL |
GM-CSF and IL-4; 3 |
s.c.,1/2 wks (× 3)+1 at 6th wks |
Increased IFN-γ |
-- |
| [11] |
Phase I/II |
14 |
N-GBM(n=1) and AA (n=1); R-GBM(n=9) and AA(n=3) |
ATL |
CM-CSF and IL-4 |
s.c. 1 /2 wks (× 3) |
Increased IFN-γ mRNA |
Med OS; 133 wks |
| [7] |
Phase I |
7 |
EM (n=3); GBM(N=2); AA(n=1); PA(n=1); MB(n=1); PXAs (n=1) |
Tumor tissue RNA |
GM-CSF and IL-4 |
i.v. and i.d. ½ wks × 2+1/1 mth (× 5) |
一 |
一 |
| [9] |
Case report |
1 |
AA |
ATL |
GM-CSF and IL-4; TNF-α, IL-1β, and PGE2 |
i.d. ½ wks (× 2)+1/1 mth (× 6) |
DTH(+) |
PFS(60m) |
| [8] |
Phase I |
12 |
HGG (n=8), AA(n=4) |
ATL |
GM-CSF and IL-4; TNF-α, IL-1β, and PGE2 |
i.d. 1 at 1st w+2 at 2nd+1/1 mth |
DTH(+) |
CCR(1), NC(3), PD(3); Med OS: 42.0 wks |
| [10] |
Phase I/II |
15 |
GBM(n=6); AA(n=9) |
ATC |
FCs and rhIL-12 GM-CSF, IL-4, and TNF-α; |
i.d , s.c. ½ wks (× 6) |
increased IFN-γ, |
PR (1), MR(1), NC (1), PD(3) |
| [13] |
Phase I |
12 |
N-GBM(n=7); R-GBM(n=5) |
Acid-eluted ATCP |
GM-CSF and IL-4 |
i.d. 1/2-4 wks (× 3) |
Tumor specific CTL; |
Med PFS: 15.5 m Med OS: 23.4 m |
| [12] |
Phase/Ⅱ |
24 |
R-AA(n=6); GBM(n=18) |
ATL |
GM-CSF and IL-4; OK-432 |
i.d. or i.d. combined i.t. (ommaya) 1/3 wks |
DTH(+); increased tumor specific CTLs |
Med OS 480d; PR(1), MR(3), NC(6), PD(8) |
| [14] |
PhaseⅠ |
7 |
R-GBM ; AA |
irradiated ATC and TFG-IL4-Neo-TK-transfected fibroblast |
UPCI95-033 UPCI 99-111 |
i.d. 1 st in D1+2nd in D7 +1/2 wks |
CD4+, CD8+ IFN-γ against EphA2883–89; HLA-A2 |
UPCI95033: Stable disease 4m (n=2) UPCI99-111: Med PFS 6m |
| [16] |
PhaseⅡ |
34 |
N-GBM(n=11); R-GBM(n=23) |
ATL |
GM-CSF and IL-4 |
s.c. ½ wks (× 3)+1st wk#6 |
increased IFN-γ |
N-GBM OS: 642 ± 61d; PFS: 308 ± 55d; R-GBM OS: 599 ± 75d; PFS: 401 ± 53d |
| [24] |
Phase I |
13 |
GBM(n=9) and AA(n=4) |
ATC |
GM-CSF and IL-4 |
i.d. ½ wks (× 6)+1/6 wks |
Increased T cell infiltration |
Med OS: 11m |
| [15] |
Phase/Ⅱ |
56 |
R-GBM |
ATL |
GM-CSF and IL-4; TNF-α, IL-1β, and PGE2 |
i.d. G1: 1st, 1w, 2nd, 3 w, ¼ wks; G2: ½ wks (× 5), ¼ w; G3: 1/1 w (× 4) |
DTH(+) |
Med PFS 3m; OS, 9.6m. |
|
[17] |
Phase/Ⅱ |
45 |
HGG(n=33), MB/PNET(n=5), EM(n=4) and ATRT(n=3) |
ATL |
GM-CSF and IL-4 |
i.d. G1: 1st, 1 w, 2nd, 3 w, ¼ w; G2: ½ w (× 5), ¼ w; G3: 1/1 w (× 4), ATL; G4: 1/1 w (× 4) |
一 |
HGG: Med OS 13.5m |
| [18] |
Phase/Ⅱ |
8 |
N-GBM |
ATL |
GM-CSF and IL-4; TNF-α, IL-1β, and PGE2 |
i.d. 1/1 w (× 4)+1/2 wks (vacc+ATL) |
increased CD8+CD25+cell, T-cell IFN-γ |
Med OS: 24m; PFS: 18m |
| [19] |
Phase I/II |
17 |
N-GBM, AA and R-GBM, AA |
ATL |
INF-Y |
S.C 1/1wks (× 4)+1/2 wks (× 2)+1/2 mth (× 4) |
Increased TIL |
GBM:Med:OS 520d |
| [42] |
PhaseⅠ |
5 |
R-HGG |
Stem-like associate antigen |
GM-CSF and IL-4 |
½ w (× 3)+poly–ICICI M1/2 wks |
一 |
一 |
| [21] |
RCT Phase II |
34 |
N- GBM and R- GBM |
ATL |
GM-CSF and IL-4 |
s.c. 1/1 w (× 4)+½ wks (× 2) +1/4 wks (× 4) |
一 |
Med OS: 31.9m; Med PFS: 8.5m |
| [22] |
Phase II |
25 |
N-and R- GBM |
ATC antigen by heat-shock |
GM-CSF and IL-4 |
i.d. 1st in D7+2nd in D14+3Rd in D28+4th in D42 |
一 |
Med OS: 17 m |
| [23] |
Phase I |
34 |
GBM(27) and AA(7) |
ATL, GAA |
GM-CSF and IL-4 |
½ wks+1/3 mth |
Lymphocyte subset change |
ATL/GAA; Med OS 34.4m/15.5m |
